Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4462
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Antibodies.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Alfacell
Algeta
Allos Therapeutics
ALSP
Altor BioScience
Ambit Biosciences
Amgen
Amorfix Life Sciences
Antisoma
Aphios
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Bayer
Benitec
Berkeley Lab
Bio-Path Holdings
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
Biolex
BioLineRx
BioSante
Biosceptre
Biotecnol
Biotest
Bioton
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Innovations
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
CSL
Curacyte
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dompe
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Ergon Pharmaceuticals
Erimos
Esperance Pharmaceuticals
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Forma Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gemin X Biotechnologies
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
GlycoMimetics
Glycotope
Green Cross
Hanmi
Hawthorn Pharmaceuticals
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immutep
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
Kaketsuken
KaloBios
Kanisa
Kinex
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
Medarex
MediGene
MedImmune
Memgen
Menarini
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mologen
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
Novogen
Noxxon
Nycomed Pharma
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Onyvax
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaMar
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shanghai CP Guojian
Shenogen
Shire
Sidus
Southern Research Institute
Spirogen
Stainwei Biotech
Stemline Therapeutics
Sunol Molecular
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
ThromboGenics
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
Wakunaga
Valeant
VasGene Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
amonafide malate
amrubicin hydrochloride
amsacrine
AV-299
barasertib
belimumab
belinostat
bevacizumab
bexarotene
BHQ880
bisantrene
blinatumomab
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
BT-062
carlumab
catumaxomab
CDX-1307
CDX-1401
cetuximab
cixutumumab
cladribine
clofarabine
CMAB302
CMAB304
conatumumab
CSF-GM
CT-011
cytarabine ocfosfate
cytarabine, injectable
dalotuzumab
daratumumab
dasatinib
daunorubicin
decitabine
denileukin diftitox
denosumab
elacytarabine
elliptinium acetate
elotuzumab
EMD-273063
EMD525797
enocitabine
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
farletuzumab
figitumumab
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GS-6634
HBP-347
histamine dihydrochloride
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idarubicin
imatinib mesilate
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
intetumumab
IPH-2102
ipilimumab
iratumumab
irinotecan hydrochloride
L19-TNFalpha
lestaurtinib
leukemia vaccine
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MEDI-551
MEDI-573
midostaurin
milatuzumab
milatuzumab-doxorubicin
mitoxantrone
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
naptumomab estafenatox
natalizumab
necitumumab
nilotinib
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaratumab
ON-01910
onartuzumab
Onyvax-105
oregovomab
panitumumab
panobinostat
PAT-SC1
peginterferon alfa-2b
pentostatin
pertuzumab
PF-4856884
pixantrone
pralatrexate
ramucirumab
razoxane
Reditux
RG-7160
rhIFN-alpha
rilotumumab
rituximab
robatumumab
romidepsin
romiplostim
samalizumab
SAR-3419
siltuximab
sobuzoxane
sotatercept
Sym-004
tamibarotene
temsirolimus
Tenarad
teniposide
tigatuzumab
tipifarnib
tocilizumab
TRC-105
tremelimumab
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
veltuzumab
volociximab
vosaroxin
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Antibodies.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the compound strategy of Antibodies. Learn More